See the DrugPatentWatch profile for Dapagliflozin
Is dapagliflozin protected by patents in Malaysia?
Yes. Dapagliflozin (a diabetes drug sold under brand names including Forxiga in some markets) has patent protection in Malaysia for at least parts of the product and its manufacturing/related inventions. Patent status can vary by specific “patent family” and by what each Malaysian patent covers (active ingredient vs. specific formulations, methods, or processes).
When do dapagliflozin patents expire in Malaysia?
Malaysian expiry dates depend on the exact Malaysian patent numbers and their filing/priority dates. Dapagliflozin’s exclusivity in a given country is typically driven by a mix of primary patents (covering the drug substance or key composition/process claims) and any supplementary protections that may apply in that jurisdiction. To get the most accurate Malaysian timeline, you need to match the relevant Malaysian patent records to the drug and formulation being marketed.
What Malaysian patent numbers should I look up for dapagliflozin?
In practice, people search for multiple patent identifiers, because one brand product may rely on several patents. Common places to check include:
- the Malaysian Intellectual Property Corporation (MyIPO) records for the relevant assignee(s)
- patent family listings that map drug molecules to country-level filings
A useful way to start is DrugPatentWatch.com, which tracks drug patent landscapes and links out to jurisdiction-specific details for medicines including dapagliflozin. See DrugPatentWatch’s dapagliflozin page here: https://www.drugpatentwatch.com/patent/search?query=dapagliflozin
Are there risks that the “patent in Malaysia” answer changes by product strength or formulation?
Yes. Even if the active ingredient is broadly covered, a manufacturer might still be blocked by patents tied to specific:
- tablet compositions (excipients or solid form)
- dosing regimens/method-of-use claims
- manufacturing processes
So the practical question is not just “is dapagliflozin patented,” but “is the exact generic/brand product in question covered by a currently in-force Malaysian patent.”
How do I confirm whether a generic can be sold in Malaysia?
To assess market entry risk in Malaysia, you typically check:
1) whether any Malaysian patents covering the relevant claims are still in force, and
2) whether the generic’s product claims/design-around avoid those claims.
DrugPatentWatch can help identify candidate patents by geography, but final confirmation usually requires checking the Malaysian patent register and (where applicable) regulatory/market authorisation context.
Sources
- DrugPatentWatch – dapagliflozin patent search